Patient Leaflet Updated 06-Jun-2024 | AstraZeneca UK Limited
Tezspire 210 mg Solution for injection in pre-filled syringe
Tezspire® 210 mg solution for injection in pre-filled syringe
tezepelumab
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.
1. What Tezspire is and what it is used for
2. What you need to know before you use Tezspire
3. How to use Tezspire
4. Possible side effects
5. How to store Tezspire
6. Contents of the pack and other information
Tezspire contains the active substance tezepelumab, which is a monoclonal antibody. Antibodies are proteins that recognise and bind to a specific target substance in the body, which in the case of tezepelumab is a protein called thymic stromal lymphopoietin (TSLP). TSLP plays a key role in causing the inflammation in your airways that leads to the signs and symptoms of asthma. By blocking the action of TSLP, this medicine helps to reduce inflammation and asthma symptoms.
Tezspire is used with other asthma medicines to treat severe asthma in adults and adolescents (12 years of age and older) when the disease is not controlled with their current asthma medicines.
Tezspire may reduce the number of asthma attacks you experience, improve your breathing and reduce your asthma symptoms.
Talk to your doctor, pharmacist or nurse before using Tezspire.
Talk to your doctor about how to recognise early signs of allergy, and how to manage reactions if they occur.
If you notice any of these signs, speak to a doctor or nurse immediately.
If you already have a serious infection, talk to your doctor before taking Tezspire.
If you notice any of these symptoms, speak to a doctor or nurse immediately.
Do not give this medicine to children under 12 years of age because the safety and benefits of this medicine are not known in children in this age group.
Tell your doctor or pharmacist:
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
Tezspire is unlikely to affect your ability to drive and use machines.
This medicine contains less than 1 mmol sodium (23 mg) per 210 mg dose, that is to say essentially ‘sodium-free’.
Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor, pharmacist or nurse if you are not sure.
Your doctor or nurse will decide if you can inject yourself or if your caregiver can do that for you. If so, you or your caregiver will receive training on the right way to prepare and inject Tezspire.
Before injecting Tezspire yourself, carefully read the ‘Instructions for Use’ for Tezspire pre-filled syringe. Do this each time you get another injection. There may be new information.
Do not share Tezspire pre-filled syringes or use a syringe more than one time.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Seek medical attention immediately if you think you may be having an allergic reaction. Such reactions may happen within hours or days after the injection.
Not known (the frequency cannot be estimated from the available data)
Common (these may affect up to 1 in 10 people)
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
Do not throw away any medicines via wastewater. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
Tezspire is a clear to opalescent, colourless to light yellow solution.
Tezspire is available in a pack containing 1 single-use pre-filled syringe.
This leaflet was last revised in 11/2023
© AstraZeneca 2023
Tezspire is a registered trademark of the AstraZeneca group of companies.
RSP 23 0068
Other sources of information
To listen to or request a copy of this leaflet in Braille, large print or audio please call, free of charge:
0800 198 5000
Please be ready to give the following information:
Product name Reference number
Tezspire 210 mg 17901/0365
This is a service provided by the Royal National Institute of the Blind.
2 Pancras Square, 8th Floor, London, N1C 4AG, UK
+44 (0)1582 838 000
www.myazmed.co.uk
+44 (0)1582 836 000
0800 783 0033
https://medicalinformation.astrazeneca.co.uk/